September the 20th will be the date to present the Spanish Observatory of Medicinal Cannabis (OECM). The event will bring together leading national and international experts in the study of the therapeutic properties of this plant.
The presentation day will be held on September 20 at the Auditorium of the Caixaforum in Madrid (Paseo del Prado, 36). It will be from 08.30 h to 17.30 h, divided into three themes:
- Presentation medicinal cannabis.
- Models of regulation of medical cannabis.
- Encounter with patients.
Leading experts from different countries of the world in the study and the use of medicinal cannabis will participate in the presentation. Among them are professional who, most likely, will enter as a part of the future history of medicine books, as it is the case of the Dr. Raphael Mechoulam from the Hebrew University of Jerusalem (Israel). Mechoulan chemically characterized for the first time the plant’s cannabinoids and endocannabinoids.
This will be the first time in Spain, in a totally free way, when researchers, doctors and patients will meet with all those wishing to learn about the possible medicinal uses of cannabis. The afternoon session will allocate the debate between patients and experts around the following diseases: childhood epilepsy, cancer, inflammatory bowel disease, pain and neurodegenerative diseases.
The OECM was born as platform created by experts (researchers, doctors and patients associations) in order to provide evidence-based information and promote, coordinate, and carry out activities and projects aimed at understanding the properties and medicinal uses of cannabis and its derivatives. Its objectives are focused on train and inform about the therapeutic properties and the use of cannabis as a medicine.
Likewise, the OECM aims to advise public and private entities and inform institutions, media, patients and therapeutic users about the current knowledge on the properties and medicinal uses of cannabis and its derivatives, based on the results of scientific studies and clinical trials.